Maze Therapeutics, Inc.
Maze Therapeutics, Inc. (MAZE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · MAZE · as of Sep 30, 2025
Ownership Breakdown
95
Institutional Holders
▲ 20 vs Q2
$1.11B
Total Inst. Value
▲ $637.50M vs Q2
55.35M
Shares Outstanding
freeFloat 28.87%
42.97M
13F Shares Held
▲ 4.13M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
MAZE largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
TRV GP IV, LLC biological products, (no diagnostic substances) | 6.07M | 13.85% | 13.85% | $157.50B | Nov 13, 2025 | — held |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. biological products, (no diagnostic substances) | 4.57M | 10.42% | 10.42% | $118.43B | Nov 14, 2025 | ▼ 1 |
ARCH VENTURE MANAGEMENT, LLC biological products, (no diagnostic substances) | 4.12M | 9.40% | 9.40% | $106.83B | Nov 14, 2025 | — held |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 3.95M | 9.01% | 9.01% | $102.40B | Nov 14, 2025 | — held |
ALPHABET INC. biological products, (no diagnostic substances) | 2.41M | 5.50% | 5.50% | $62.56B | Nov 7, 2025 | — held |
AH CAPITAL MANAGEMENT, L.L.C. biological products, (no diagnostic substances) | 1.70M | 3.88% | 3.88% | $44.14B | Nov 14, 2025 | — held |
MATRIX CAPITAL MANAGEMENT COMPANY, LP biological products, (no diagnostic substances) | 1.65M | 3.77% | 3.77% | $42.88B | Nov 13, 2025 | ▼ 832.5K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.33M | 3.04% | 3.04% | $34.62B | Nov 7, 2025 | ▲ 915.3K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 1.32M | 3.00% | 3.00% | $34.12B | Nov 12, 2025 | ▲ 701.3K |
VR ADVISER, LLC biological products, (no diagnostic substances) | 1.23M | 2.81% | 2.81% | $31.91B | Nov 14, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
21
Increased
+5.24M shares9
New Positions
first time holders8
Decreased
−4.10M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.14M
+5.24M / −4.10M
Net new holders
+22
9 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
MAZE insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
19
Sell transactions
0.32
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Coloma Jason V Chief Executive Officer | Jun 1, 2026 | Sale | 6,090 | $26.20 | $159.5K | 344.9K | Form 4 ↗ |
Coloma Jason V Chief Executive Officer | Jun 1, 2026 | Sale | 553 | $26.24 | $14.5K | 28.0K | Form 4 ↗ |
Bernstein Harold President, R&D & CMO | Jun 1, 2026 | Sale | 13,253 | $25.57 | $338.9K | 1.6K | Form 4 ↗ |
Bernstein Harold President, R&D & CMO | Jun 1, 2026 | Sale | 1,600 | $26.36 | $42.2K | 0 | Form 4 ↗ |
Dandekar Atul CSBO | May 29, 2026 | Sale | 7,500 | $26.34 | $197.6K | 24.8K | Form 4 ↗ |
Coloma Jason V Chief Executive Officer | May 22, 2026 | Sale | 4,504 | $26.00 | $117.1K | 376.6K | Form 4 ↗ |
Coloma Jason V Chief Executive Officer | May 26, 2026 | Sale | 25,582 | $26.02 | $665.5K | 351.0K | Form 4 ↗ |
Coloma Jason V Chief Executive Officer | May 22, 2026 | Sale | 2,478 | $26.00 | $64.4K | 28.5K | Form 4 ↗ |
Coloma Jason V Chief Executive Officer | May 15, 2026 | Sale | 1,822 | $26.00 | $47.4K | 381.1K | Form 4 ↗ |
Coloma Jason V Chief Executive Officer | May 15, 2026 | Sale | 116 | $26.00 | $3.0K | 31.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Maze Therapeutics, Inc. (MAZE) is primarily owned by institutional investors, who hold approximately 77.6% of total shares outstanding. Company insiders own approximately 71.13%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Maze Therapeutics, Inc. is TRV GP IV, LLC, holding approximately 6.07 million shares — equal to 13.85% of outstanding shares — as of September 30, 2025.
A total of 95 institutional investors currently hold MAZE stock, with a combined institutional value of approximately $1.11 billion as of the most recent 13F filing period.
Frequently asked questions
MAZE ownershipMaze Therapeutics, Inc. (MAZE) is primarily owned by institutional investors, who hold approximately 77.6% of shares. The largest shareholder is TRV GP IV, LLC with a 13.85% stake. Company insiders hold 71.13%. Data sourced from SEC Form 13F as of September 30, 2025.